Results 41 to 50 of about 4,268 (199)

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking.
Mohammed W. Ali, Sam Nightingale, Tracy Kellermann, John Joska, Alan Winston, Saye Khoo, Joseph F. Standing, Eric H. Decloedt, Ahmed A. Abulfathi   +8 more
wiley   +1 more source

Palladacarboxamide Capping Reagents for Carbon Isotope Labeling and Pharmaceutical Diversification

Angewandte Chemie, Volume 138, Issue 28, 6 July 2026.
Herein, we present a method for carbon isotope labeling of arylamides via the coupling of air‐stable palladium carboxamide complexes and boronic ester/acids. A wide variety of functionalized boronic esters and acids have been coupled with simple palladium carboxamides complexes.
Daniel V. Hoffmann, Anika Schick, Lasse Kjær, Vitus J. Enemærke, Clemens Kaussler, Jens Torp, Pablo Martínez‐Pardo, Charles S. Elmore, Troels Skrydstrup   +8 more
wiley   +2 more sources

Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention

Infectious Diseases and Therapy
Introduction The efficacy of long-acting injectable cabotegravir (hereafter referred to as cabotegravir) versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) was demonstrated in two phase 3 ...
Neil Hawkins, Paul O’Brien, Juliette Thompson, Sarah-Jane Anderson, Eric Manalastas, Laure Dupont-Benjamin, Melanie Schroeder   +6 more
doaj   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans, Abdulwahhab Khedr, Panagiotis G. Georgiou, Nehir Arik, Ozlem Sen, Steve P. Rannard, Tom O. McDonald, Christos Tapeinos   +7 more
wiley   +1 more source

Mechanistic Basis of Cabotegravir–Glucuronide Disposition in Humans [PDF]

The Journal of Pharmacology and Experimental Therapeutics, 2019
Cabotegravir, a novel integrase inhibitor under development for treatment and prevention of HIV, is primarily metabolized by UDP-glucuronosyltransferase (UGT)1A1 and UGT1A9 to a direct ether glucuronide metabolite. The aim of these studies was to elucidate the mechanistic basis of cabotegravir-glucuronide disposition in humans.
Mitesh, Patel, H Christian, Eberl, Andrea, Wolf, Esaie, Pierre, Joseph W, Polli, Maciej J, Zamek-Gliszczynski   +5 more
openaire   +2 more sources

Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load

Viruses
Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) is currently approved as a maintenance therapy for people with HIV (PWH) who are virologically suppressed.
Marcello Trizzino, Luca Pipitò, Pierluigi Francesco Salvo, Federica Zimmerhofer, Andrea Cicero, Gianmaria Baldin, Claudia Conti, Claudia Gioè, Simona Di Giambenedetto, Antonio Cascio   +9 more
doaj   +1 more source

Predicting Oral HIV Pre‐Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy.
Yifan Yu, Kristina M. Brooks, Gustavo F. Doncel, Brookie M. Best, Mark A. Marzinke, Mark Mirochnick, Peter L. Anderson, Landon Myer, Connie Celum, Renee Heffron, Jenell Coleman, Dvora L. Joseph Davey, Lanxin Zhang, Max von Kleist, Craig W. Hendrix, Jeremiah D. Momper, Robert Bies, Rachel K. Scott   +17 more
wiley   +1 more source

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults [PDF]

, 2020
BackgroundLong-acting (LA) formulations of cabotegravir, an HIV integrase inhibitor, and rilpivirine, an NNRTI, are in development as monthly or 2 monthly intramuscular (IM) injections for maintenance of virological suppression.ObjectivesTo evaluate ...
Bettacchi, Christopher, Swindells, Susan, Devente, Jerome, Sutton, Kenneth, Patel, Parul, Mills, Anthony, Hagins, Debbie, Lou, Yu, Ford, Susan, Felizarta, Franco, Shaik, Jafar Sadik, D’Amico, Ronald, Letendre, Scott L, Crauwels, Herta   +13 more
core   +1 more source

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects [PDF]

Clinical Pharmacology in Drug Development, 2016
AbstractA randomized, partial‐blind, repeat‐dose, 3‐period crossover study (NCT02027454) assessed the effect of cabotegravir on QT interval in healthy subjects. To achieve a supratherapeutic dose, each subject received cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days, matching placebo (every 12 hours) over 2 ...
Lou, Yu, Buchanan, Ann M., Chen, Shuguang, Ford, Susan L., Gould, Elizabeth, Margolis, David, Spreen, William R., Patel, Parul   +7 more
openaire   +2 more sources

Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro

Frontiers in Medicine, 2022
Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus most prevalent in southwestern Japan, sub-Saharan Africa, Australia, South America, and the Caribbean. Latest figures approximate 10 million people worldwide to be infected with HTLV-1.
Bethany S. Schneiderman, Michal S. Barski, Goedele N. Maertens   +2 more
doaj   +1 more source